Chinese Journal of Lung Cancer (Sep 2011)

Advances of Targeted Therapy Based on Estrogen Receptor Signaling Pathway 
in Lung Cancer

  • Liqiang XU,
  • Yongde LIAO,
  • Hexiao TANG,
  • Chao ZHANG,
  • Zhaoguo LIU

DOI
https://doi.org/10.3779/j.issn.1009-3419.2011.09.07
Journal volume & issue
Vol. 14, no. 9
pp. 727 – 732

Abstract

Read online

Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target organs and non-target organs. Estrogen regulates cell proliferation and differentiation via two different receptors, estrogen receptors α and β (ERα and ERβ). In recent decades, with the clarification of the ERα-mediated signaling pathways in breast cancer, targeted therapy through these pathways have successfully been used in clinical application. Tamoxifen, the classic representative, is a selective estrogen receptor modulator (SERM). Along with the elucidation of the role of estrogen in the pathophysiology of lung cancer, targeted lung cancer treatment based on the ER signaling pathways is also gradually being applied and it could become an important part of the comprehensive treatment for lung cancer.

Keywords